Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BMRA vs TCMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TCMD Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

TCMD Overall Winner 6-Pillar Tally: BMRA 0 – 6 TCMD Matrix Metrics: BMRA 1 – 9 TCMD

As of Nov 16, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas TCMD carries 25.0/100 (SELL) at $26.36 (18.2x Forward P/E, 9.4% operating margin).

  • Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. TCMD 25.0/100 SELL), TCMD captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (9.4% vs. -125.2% operating margin) and revenue trajectory (+7.1% vs. -8.3% YoY).
  • Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile TCMD trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BMRA vs TCMD
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.36
+0.0% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96
TCMD NASDAQ Head-to-Head Winner
Tactile Systems Technology, Inc.
Surgical & Medical Instruments & Apparatus
$26.36
-1.68% 1D
Market Cap $601.1M
TTM Revenue $356M
Forward P/E 18.2x
Beta / 30D Vol 1.07β · 53% Vol
Unified Composite Score
25.0 / 100 SELL
Tech 50.0 Fund 27.0 Flow 66.0 Mom 21.4
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.3% over 20 days), RSI 61
RSI-14: 60.6 · SMA20: $24.98 · SMA50: $23.45

6-Pillar Scorecard Institutional Category Breakdown (BMRA 0 – 6 TCMD)

Columns: Metric · BMRA · TCMD
1. Valuation Multiples TCMD
Forward P/E N/M 18.2x
Trailing P/E N/M 26.1x
PEG Ratio N/M 17.79x
EV / Revenue 1.1x 1.5x
2. Growth & Scale TCMD
Revenue Growth (YoY) -8.3% +7.1%
Earnings Growth (YoY) +0.0% -13.9%
TTM Revenue (USD) $4.3M $356M
Market Cap $6.0M $601.1M
3. Profitability & Quality TCMD
Gross Margin 0.9% 77.0%
Operating Margin -125.2% 9.4%
Net Profit Margin -115.5% 6.7%
Return on Equity (ROE) -113.8% 11.0%
4. Balance Sheet & Cash Flow TCMD
Cash Generation (TTM) -$3.2M $29M
Cash Flow Margin -73.5% 8.1%
Net Cash / Leverage $1.1M Net Cash $58M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TCMD
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 54.9% (15th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat TCMD
OpEx & R&D Intensity N/A 67.6% of Rev ($241M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BMRA (1) vs TCMD (9)
Institutional Metric BMRA TCMD Criterion Row Edge
Market Capitalization
Scale
$6.0M $601.1M Larger Scale TCMD
Trailing P/E Ratio
Valuation
N/M 26.1x Lower Multiple TCMD
Forward P/E Ratio
Valuation
N/M 18.2x Lower Multiple TCMD
Revenue Growth (YoY)
Growth
-8.3% +7.1% Higher Growth TCMD
Operating Margin (TTM)
Profitability
-125.2% 9.4% Higher Margin TCMD
Net Profit Margin
Profitability
-115.5% 6.7% Higher Margin TCMD
Return on Equity (ROE)
Capital Efficiency
-113.8% 11.0% Higher ROE TCMD
52-Week Range Position
Momentum
5% ($1–$3) 34% ($21–$38) Stronger Trend TCMD
Beta / 30D Volatility
Risk Regime
0.67β · 62% Vol 1.07β · 53% Vol Lower Realized Risk TCMD
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 25.0 / 100 (SELL) Higher Composite BMRA
Trailing 12M Revenue (USD)
Operating Scale
$4.3M $356M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.9% 77.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.1x EV/Rev 17.79x PEG · 1.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.2M ($1.1M Net Cash) $29M ($58M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TCMD +43.54 pp
BMRA: -26.49% · TCMD: +17.05%
3M Horizon TCMD +25.52 pp
BMRA: -15.0% · TCMD: +10.52%
6M Horizon TCMD +51.02 pp
BMRA: -39.56% · TCMD: +11.46%
1Y Horizon TCMD +53.77 pp
BMRA: -45.6% · TCMD: +8.17%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BMRA Revenue TCMD Revenue BMRA Op. Margin TCMD Op. Margin Margin Leader
FY2019 $10M $190M -46.4% 5.5% TCMD
FY2020 $10M $190M -41.0% -1.9% TCMD
FY2021 $10M $210M -104.2% -0.8% TCMD
FY2022 $20M $250M -24.0% -5.2% TCMD
FY2023 $10M $270M -135.3% 6.6% TCMD
FY2024 $10M $290M -117.6% 7.6% TCMD
FY2025 $10M $330M -96.7% 8.9% TCMD
FY2026 $0M N/A -119.5% N/A BMRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TCMD CONSOLIDATION
94d in phase · OBV ACCUMULATION
Current IV 54.9%
IV Percentile 15th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact TCMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TCMD Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $601.1M market capitalization and 9.4% operating margin.
OpEx & R&D Reinvestment 67.6% of Rev ($241M)
90D Engineering Disclosures 0 Published

Investor FAQ BMRA vs TCMD Key Questions & Quantitative Answers

As of Nov 16, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas TCMD carries 25.0/100 (SELL) at $26.36 (18.2x Forward P/E, 9.4% operating margin). Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. TCMD 25.0/100 SELL), TCMD captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (9.4% vs. -125.2% operating margin) and revenue trajectory (+7.1% vs. -8.3% YoY). Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile TCMD trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TCMD leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with TCMD at +7.1% YoY revenue growth and -13.9% YoY earnings growth on $356M TTM revenue (77.0% gross margin, 9.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BMRA cumulative revenue shifted +0.0% while TCMD shifted +73.7%. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus 67.6% of Rev ($241M) (0 disclosures) for TCMD.

TCMD screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas TCMD trades at 18.2x Forward P/E, 26.1x Trailing P/E, 17.79x PEG, and 1.5x EV/Revenue (8.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus TCMD (11.0% ROE) capital efficiency.

In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, TCMD carries 54.9% implied volatility (15th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 53% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.